Short Interest in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Rises By 45.1%

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) was the target of a significant growth in short interest during the month of December. As of December 31st, there was short interest totaling 2,118,631 shares, a growth of 45.1% from the December 15th total of 1,459,615 shares. Based on an average daily trading volume, of 1,301,783 shares, the days-to-cover ratio is currently 1.6 days. Currently, 5.7% of the shares of the company are sold short. Currently, 5.7% of the shares of the company are sold short. Based on an average daily trading volume, of 1,301,783 shares, the days-to-cover ratio is currently 1.6 days.

Werewolf Therapeutics Price Performance

Shares of NASDAQ HOWL traded down $0.00 during trading hours on Friday, reaching $0.55. 571,259 shares of the stock traded hands, compared to its average volume of 619,783. The company has a market capitalization of $26.66 million, a P/E ratio of -0.34 and a beta of 0.77. The company’s 50-day simple moving average is $0.83 and its two-hundred day simple moving average is $1.23. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.73. Werewolf Therapeutics has a 52-week low of $0.53 and a 52-week high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.03. Equities research analysts forecast that Werewolf Therapeutics will post -1.56 EPS for the current year.

Insider Activity

In other news, Director Luke Evnin sold 58,980 shares of the stock in a transaction on Monday, January 12th. The stock was sold at an average price of $0.57, for a total transaction of $33,618.60. Following the completion of the transaction, the director owned 2,309,869 shares in the company, valued at approximately $1,316,625.33. This represents a 2.49% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 5,980,336 shares of company stock valued at $6,503,824 in the last 90 days. Insiders own 23.60% of the company’s stock.

Institutional Investors Weigh In On Werewolf Therapeutics

Institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC purchased a new position in Werewolf Therapeutics during the 2nd quarter valued at $409,000. Citadel Advisors LLC purchased a new position in shares of Werewolf Therapeutics during the third quarter valued at about $304,000. Vanguard Group Inc. raised its stake in Werewolf Therapeutics by 8.5% in the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock worth $2,774,000 after buying an additional 109,796 shares in the last quarter. Marshall Wace LLP bought a new position in Werewolf Therapeutics in the second quarter worth about $113,000. Finally, Y Intercept Hong Kong Ltd purchased a new stake in Werewolf Therapeutics in the second quarter worth about $92,000. 64.84% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

HOWL has been the subject of a number of recent analyst reports. Citigroup lowered Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a report on Friday, December 19th. Bank of America cut their price objective on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research report on Tuesday, November 18th. Wedbush cut shares of Werewolf Therapeutics from an “outperform” rating to a “neutral” rating and set a $1.00 target price on the stock. in a research note on Friday, December 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, October 8th. Finally, Citizens Jmp lowered shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, December 19th. Three investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $3.75.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.